Response of Topical Capsaicin in Alopecia Areata

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT00176969
First received: September 12, 2005
Last updated: May 30, 2014
Last verified: May 2014

September 12, 2005
May 30, 2014
August 1997
Not Provided
Topical capsaicin will quantitatively decrease the amount of Substance P in the scalp of AA patients.
Same as current
Complete list of historical versions of study NCT00176969 on ClinicalTrials.gov Archive Site
The scalps of AA patients may be less sensitive to stimuli.
Same as current
Not Provided
Not Provided
 
Response of Topical Capsaicin in Alopecia Areata
Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin

It has been postulated that Alopecia Areata (AA) is, at least in part, a neurologically mediated disease. Research supporting this theory includes the finding that nerves surrounding the hair follicles are collapsed. We want to take this research a step further and show that not only are these perifollicular nerves collapsed, but that their function is also impaired.

To assess the function of perifollicular scalp nerves in AA we will look at the response of these nerves to the topical medication capsaicin. Under normal circumstances topical capsaicin is known to target nerves in the peripheral nervous system causing short-term release of the neuropeptide Substance P (SP) as well as long-term transient depletion of SP. We expect the AA patients will respond abnormally to topical capsaicin treatment.

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Alopecia Areata
Drug: Capsaicin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
June 2000
Not Provided

Inclusion Criteria:

  • Must have alopecia totalis or universalis.
  • Be in good health.
  • Not be taking any medications including topical medications
  • Be 18 years or older.
  • Be willing to apply study medication or vehicle as directed, comply with instructions and commit to follow-up visits.
  • Not have had hair chemically treated (including colored hair, permed hair, etc) within the month prior to the study.

Exclusion Criteria:

  • Absence of extensive alopecia areata.
  • People not in good health.
  • People taking medications.
  • Allergies to capsaicin.
  • Presence of irritated or visibly inflamed scalp.
  • Having had hair chemically treated (including colored hair, permed hair, etc.) within the month prior to study.
Both
18 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00176969
9707M00122
Yes
University of Minnesota - Clinical and Translational Science Institute
University of Minnesota - Clinical and Translational Science Institute
Not Provided
Principal Investigator: Maria Hordinsky, MD University of Minnesota - Clinical and Translational Science Institute
Principal Investigator: Marna Ericson, Ph D University of Minnesota - Clinical and Translational Science Institute
University of Minnesota - Clinical and Translational Science Institute
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP